Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study

Abstract excerpt

Abstract Introduction Individual variability of rivaroxaban was observed in clinical application. This study aimed to identify genetic variants associated with the variability of pharmacodynamics and bleeding risk of rivaroxbaban in patients with nonvalvular atrial fibrillation (NVAF). Materials and Methods From June 2017, and July 2019, this study enrolled 257 patients with NVAF receiving rivaroxaban....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Atrial Fibrillation Management and Outcomes
• Share to Blood Coagulation and Thrombosis Mechanisms
• Share to Genomics and Rare Diseases